Home LiteratureArticle Details
PMID: 30881965 Published · ppublish English Editorial Comment

Cabozantinib and the moving field of systemic treatments in advanced hepatocellular carcinoma.

Hepatobiliary surgery and nutrition ·Vol. 8 ·No. 1 ·2019-02-00 ·Pages 53-55

Allaire M, Nault JC

Abstract

暂无摘要

Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Allaire Manon
Service d'hépato-gastroentérologie et de nutrition, CHU Côte de Nacre, Caen, France. | UMR 1149, Centre de Recherche sur l'inflammation, Faculté de Médecine Bichat, Paris, France.
Nault Jean Charles
Service d'hépatologie, CHU de jean Verdier, Bondy, France. | UMR 1162, Génomique Fonctionnelle des Tumeurs Solides, Institut National de la Santé et de la Recherche Médicale, Paris, France.
Conflict of Interest

Conflicts of Interest: The authors have no conflicts of interest to declare.

References (9)
9 references, click to expand
  1. Sorafenib in advanced hepatocellular carcinoma.
    N Engl J Med. 2008 Jul 24;359(4):378-90 PMID: 18650514
  2. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
    Lancet Oncol. 2009 Jan;10(1):25-34 PMID: 19095497
  3. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet. 2017 Jan 7;389(10064):56-66 PMID: 27932229
  4. AASLD guidelines for the treatment of hepatocellular carcinoma.
    Hepatology. 2018 Jan;67(1):358-380 PMID: 28130846
  5. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
    Lancet. 2017 Jun 24;389(10088):2492-2502 PMID: 28434648
  6. Hepatocellular carcinoma.
    Lancet. 2018 Mar 31;391(10127):1301-1314 PMID: 29307467
  7. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
    Lancet. 2018 Mar 24;391(10126):1163-1173 PMID: 29433850
  8. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.
    J Hepatol. 2018 Jul;69(1):182-236 PMID: 29628281
  9. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.
    N Engl J Med. 2018 Jul 05;379(1):54-63 PMID: 29972759
Article Info
Journal
Hepatobiliary surgery and nutrition
Abbr.
Hepatobiliary Surg Nutr
ISSN
2304-3881
DOI
10.21037/hbsn.2018.10.12
Published
2019-02-00
Pages
53-55
Language
English
Region
China (Republic : 1949- )
NLM ID
101600750
PMCID
PMC6383024
Corrections
CommentOn
PMID: 29972759
External Links
PubMed source DOI: 10.21037/hbsn.2018.10.12 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2